SCHIZOPHRENIA
Recruiting for Phase 2 Study
We are currently recruiting for our Phase 2 study to evaluate the efficacy, safety, tolerability, and pharmacodynamics of SPG302 in adults with a primary diagnosis of schizophrenia.
Clinical Trials are Open in the United States and Australia:
NCT06442462
Status: Recruiting
Locations
Garden Grove, California, United States, 92845
Contact: CNS Outreach and Recruitment
844-424-9494
cns.info@cenexel.com
MAPrc, Melbourne VIC, Australia
Contact: Emorfia Gavrilidis at MAPrc
emmy.gavrilidis@monash.edu
For additional information, visit ClinicalTrials.gov
